NANO4 Global aims to provide solutions for one step molecular identification of DNA/RNA at point-of-care (PoC). NANO4 Global spins around an awarded platform — NANO4 - the next generation of molecular nanodiagnostics applied to lifesciences.

NANO4 Global is a startup launched in 2015 to market nanotechnology based molecular diagnostics. The NANO4 is a nanodiagnostics platform that provides simple colorimetric detection of DNA and RNA with single base selectivity. Following more than 12 years of research in nanodiagnostics at Universidade NOVA de Lisboa - Science and Technology, Department of Lifesciences, this technology was awarded the Scientific Prize - Santander Totta / Universidade NOVA de Lisboa.

NANO4 approach has proven track record in the detection of TB and MDRTB; NANO4 platform is being validated towards detection of ZIKA virus infection; NANO4 R&D for molecular diagnostics of other pathogens of clinical relevance: MRSA; Dengue; Salmonella sp.; Currently starting validation of CML molecular detection of BCR-ABI fusion for diagnostics and follow up;

NANO4 R&D focusing on lung and colon cancer biomarkers; NANO4 is a fast and user friendly technology suitable for POC.; NANO4 is highly specific and sensitive nanotechnology for in vitro molecular diagnostics.

Professor Pedro Baptista (co-fundador)

PhD in Human Molecular Genetics @ The School Of Pharmacy, University of London

MPharm @ Faculdade de Farmácia, Universidade de Lisboa

Site